Arena- Belviq Sales Continue To Under-Perform And Underwhelm

Arena- Belviq Sales Continue To Under-Perform And Underwhelm


Arena saw U.S. sales of Belviq continue to under-perform levels needed to impress the street this past week. Sales are 12% off of the pace established in Q4, and are down a stunning 22% from the levels we were seeing just a year ago.



from Biotech News